CPD Module 3: The COMPASS Trial

Dr Derek Connolly

The COMPASS trial was a landmark study demonstrating the benefits of low-dose (vascular dose) rivaroxaban in patients at high risk of cardiovascular events. This module provides an overview of the rational behind the COMPASS trial, the trial design and top-line results of the trial.

 QUESTIONS

Bayer have supported the videos through an unrestricted grant and have no influence on the faculty or content.

This module was filmed in May 2019.